Eric Stock
Gibson Dunn (New York)
Partner
Eric J. Stock is a Partner at Gibson Dunn. He is the former Chief of the Antitrust Bureau of the New York Attorney General’s Office (“NYAG”), a position he held for approximately three years. On June 1 2016, he became a partner at the international law firm of Gibson Dunn & Crutcher. At NYAG, Mr. Stock was responsible for enforcing New York State laws prohibiting anticompetitive business practices, and representing the interests of New York and New York consumers in national antitrust matters. In his role as Bureau Chief, Mr. Stock led the office to several important litigation victories and settlements, supervised dozens of investigations by New York, and coordinated numerous joint investigations with the federal antitrust agencies. At Gibson Dunn & Crutcher, Mr. Stock will focus his practice on antitrust litigation and investigations, with a particular emphasis on matters in the health care, pharmaceutical, high-tech, and financial services industries. Mr. Stock is past Chair of the Antitrust Section of the New York State Bar Association, and currently serves as Co-Chair of the Insurance and Financial Services Committee of the ABA Antitrust Section. He received his B.A. from the University of Pennsylvania, summa cum laude, and his J.D. from Harvard Law School, magna cum laude. Prior to 2013, Mr. Stock was a partner at Hogan Lovells.
Auteurs associés
Peter Alexiadis
Gibson Dunn (Brussels)
D. Jarrett Arp
Gibson Dunn (Washington)
Nicholas Banasevic
Gibson Dunn (Brussels)
Rachel S. Brass
Gibson Dunn (San Francisco)
Joel M. Cohen
Gibson Dunn (New York)
1719 | Évènements
Articles
7381 Bulletin
531
Important U.S. Developments Relating to “Reverse Payment” Patent Settlements* There have been two key recent developments in the U.S. relating to the legal dispute over patent settlements including so-called “reverse payments.” First, the U.S. Supreme Court has agreed to review an Eleventh Circuit (...)
393
Important U.S. Developments Relating to “Reverse Payment” Patent Settlements* There have been two key recent developments in the U.S. relating to the legal dispute over patent settlements including so-called “reverse payments.” First, the U.S. Supreme Court has agreed to review an Eleventh Circuit (...)
238
New U.S. Supreme Court Decision Addresses Pharmaceutical “Use Codes”* The U.S. Supreme Court recently issued a decision that provides generic pharmaceutical manufacturers with the ability to challenge the “use codes” listed by brand name manufacturers in filings made with the U.S. Food and Drug (...)
381
U.S. Department of Justice Litigates to Block Two Mergers* The U.S. Department of Justice (“DOJ”) has blocked two mergers in the past several months, in each case after filing a lawsuit against the merging parties. The first case involved a relatively small transaction in the digital tax (...)
336
U.S. Department of Justice Litigates to Block Two Mergers* The U.S. Department of Justice (“DOJ”) has blocked two mergers in the past several months, in each case after filing a lawsuit against the merging parties. The first case involved a relatively small transaction in the digital tax (...)
480
U.S. FTC Scrutinizes Interplay Between Authorized Generics and Patent Settlements* The U.S. Federal Trade Commission has recently released two reports relating to the pharmaceutical industry. A significant theme in both reports is a concern that brand name pharmaceutical companies are using (...)
397
U.S. FTC Scrutinizes Interplay Between Authorized Generics and Patent Settlements* The U.S. Federal Trade Commission has recently released two reports relating to the pharmaceutical industry. A significant theme in both reports is a concern that brand name pharmaceutical companies are using (...)
353
U.S. Federal Trade Commission Recommends Changes to U.S. Patent System* The U.S. Federal Trade Commission (“FTC”) has issued a report analyzing the U.S. patent system from a competition policy perspective. The FTC recognizes that, like the competitive process fostered by competition law, the (...)
881
U.S. Dep’t of Justice Targets MFN Agreements* The U.S. Department of Justice (DOJ) is seeking to curb the use of so-called “most favored nation” (MFN) agreements — a common business practice that the DOJ believes can sometimes result in anticompetitive effects when entered into by a dominant (...)
1110
New U.S. Merger Guidelines Suggest Increased Focus on Deals in High Tech and Pharmaceutical Sectors* In August 2010, the U.S. antitrust agencies released the final version of their revised Horizontal Merger Guidelines, which they use to analyze the competitive implications of mergers between (...)
433
In U.S., It’s Getting Harder to Bring Consumer Antitrust Class Actions* One of the inevitable facts of life in the U.S. after a government antitrust investigation becomes public – especially if it is a cartel investigation with an amnesty applicant or guilty pleas – is customer class actions. (...)
817
U.S. Antitrust Decisions Frequently Driven by Concerns With Burdens of U.S. Litigation Process* Many of the most important U.S. judicial decisions in antitrust have been driven by judicial concern with aspects of the U.S. litigation process that are perceived by some to impose excessive costs (...)
1031
U.S. Antitrust Decisions Frequently Driven by Concerns With Burdens of U.S. Litigation Process* Welcome to our blog ! I thought I would start my postings on U.S. developments with a broader point about recent U.S. case law in the antitrust area. Many of the most important U.S. judicial (...)
565 Revue
565
Dans cette interview, Eric J. Stock, responsable sortant du département antitrust du bureau du procureur général de New York décrit son expérience auprès du gouvernement de Jonathan Jacobson, associé chez Wilson Sonsini et vice-président du département antitrust de l’American Bar Association. Mr. Stock (...)
